# pathway_0132: before and after transfer clarification

[All 1,328 cases](../README.md) · [Method](../METHOD.md) · [Summary](../SUMMARY.md) · [Exact reviewer user message](../inputs/pathway_0132.txt)

**Task:** `pathway`  
**Author key, unchanged:** **A** — Antifungal biosynthesis. .

| Round | Reviewer | Key support | Transfer / lookup | Output usability (canonical status) |
|---|---|---|---|---|
| before | GPT-6 Luna | supported | lookup-dependent | usable output (valid_review) |
| before | Qwen3.8-Flash-Next-NVFP4 | supported | lookup-dependent | usable output (valid_review) |
| after | GPT-6 Luna | supported | lookup-dependent | usable output (valid_review) |
| after | Qwen3.8-Flash-Next-NVFP4 | supported | lookup-dependent | usable output (valid_review) |

**Usable output means format-valid review, not reasoning-supported or biologically correct.** A usable output can classify the question as reasoning-supported, lookup-dependent or uncertain. An output error is a problem with the saved model response; it does not count a defective benchmark question or wrong key. Each saved review is retained in full below. Labels from output errors are displayed as saved and excluded from label statistics. The author key and reviewer evidence were visible to reviewers; this is a review of answerability and key support, not a benchmark-solving score.

## Complete original question

```text
[Protein Sequence]
MYDVIVIGAGWCGLVAAKTYLQVCPDARLLLVDGDSSIGGTWSKERLYPHLVAEAHHGLFEFSDLPMRRDTVLPDGRIPSAAVHDYLTEYATKFDLIDRIRLNTWIENVRREPAVIGDNEAPRWMLTVAGSCEQIPTKKIIIATGLTSEPYMPFLPGRQEFEGEVLHSKALGHPQTGDRISDPSVRHAVVYGGSKSAFDAVYLLLRAGKTVDWVIREQGGGPSMMTPLSILGQPSFRLNNSRLLALFSPHPFDTTVKASWWQRVMHRRSGRLAQLAVIGFWRILAYLLQRPWKYNQSANGRRLRPLLALDSLFWSPATLGVMTHPELWDDIHSGERVTIHRQAITALGKDKRVILDNGVELSADLVVCATGWHARHTLFKPEEQLAVGLPSAVSFDPKSQSEWINLQRKADQEIIEEMPILQKSPVPSVPFRCEDDYHLYRFIAPSREPPSHERSIAYVGFLRTAGAPIVYEAQSLWATAYLTGALDVPGPSERISEVARTNAWIRRRYICGRKVPFALFDFLPYVDMLYRDLGVNPHRKANMVAEICGLYQPRDFQGVVSEWLASRGVKDIENV

[Multiple Choices]
A. Antifungal biosynthesis. .
B. L-methionine biosynthesis via de novo pathway
C. Alkaloid biosynthesis. .
D. L-valine biosynthesis
```

<details>
<summary>Complete original system instructions</summary>

```text
You are an excellent scientist. Analyze the provided protein-related task carefully and choose the correct answer from the multiple-choice options.

The current task is about Protein Pathway Prediction, which is to predict the primary metabolic or signaling pathway in which a given protein functions. Biological pathways are series of chemical reactions occurring within a cell that are essential for life. Based on the protein's amino acid sequence, you should identify the most relevant pathway from the given options.. The inputs provided by the user for this task include:

* Protein Sequence: The amino acid sequence of the protein.
* Multiple Choices: Candidate answers for the protein-related question.

Please think step-by-step about this problem:
1. Analyze the protein sequence carefully.
2. Consider the biological context and function.
3. Evaluate each multiple-choice option.
4. Provide your reasoning process.
5. Finally, give your answer.

Provide your response in the following format:
1. reasoning: [Your detailed reasoning here]
2. answer: Your final answer, which should be "A", "B", "C" or "D".
```

</details>

## Four saved visible reviews

## Before: GPT-6 Luna

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The exact sequence matches the UniProt entry for FAD-dependent monooxygenase Rstn6, annotated to the antifungal biosynthesis pathway with a PubMed-linked ECO:0000269 evidence code. This supports the key as a database annotation; it is not independent validation of the underlying study.

Citations as saved: [C4](#evidence-c4), [C5](#evidence-c5), [C6](#evidence-c6), [H3](#evidence-h3).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

> The sequence may suggest an enzyme, but no general sequence feature supplied here identifies its specific biosynthetic pathway among these choices.


**Missing item-specific fact**

> The protein's identity as Rstn6 and its pathway assignment to antifungal biosynthesis, established by protein-specific annotation and associated literature.


**Reason**

> Selecting the pathway requires the item-specific functional or pathway annotation; the sequence alone does not meaningfully distinguish the choices.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> The supplied sequence does not resolve the pathway, but the reviewer-only evidence supports one option rather than establishing multiple defensible choices.


### Important caveats

- The reviewer-only accession and pathway annotation were not supplied to the evaluated model.
- The actual source snapshot used by the author is unknown; a sequence-matched historical UniProt record also contains the pathway annotation.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence may suggest an enzyme, but no general sequence feature supplied here identifies its specific biosynthetic pathway among these choices.",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "The protein's identity as Rstn6 and its pathway assignment to antifungal biosynthesis, established by protein-specific annotation and associated literature.",
    "reason": "Selecting the pathway requires the item-specific functional or pathway annotation; the sequence alone does not meaningfully distinguish the choices."
  },
  "case_id": "pathway_0132",
  "expected_answer_check": {
    "evidence_ids": [
      "C4",
      "C5",
      "C6",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The exact sequence matches the UniProt entry for FAD-dependent monooxygenase Rstn6, annotated to the antifungal biosynthesis pathway with a PubMed-linked ECO:0000269 evidence code. This supports the key as a database annotation; it is not independent validation of the underlying study."
  },
  "important_caveats": [
    "The reviewer-only accession and pathway annotation were not supplied to the evaluated model.",
    "The actual source snapshot used by the author is unknown; a sequence-matched historical UniProt record also contains the pathway annotation."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The supplied sequence does not resolve the pathway, but the reviewer-only evidence supports one option rather than establishing multiple defensible choices."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text
{
  "case_id": "pathway_0132",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The exact sequence matches the UniProt entry for FAD-dependent monooxygenase Rstn6, annotated to the antifungal biosynthesis pathway with a PubMed-linked ECO:0000269 evidence code. This supports the key as a database annotation; it is not independent validation of the underlying study.",
    "evidence_ids": ["C4", "C5", "C6", "H3"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "The sequence may suggest an enzyme, but no general sequence feature supplied here identifies its specific biosynthetic pathway among these choices.",
    "missing_item_specific_fact": "The protein's identity as Rstn6 and its pathway assignment to antifungal biosynthesis, established by protein-specific annotation and associated literature.",
    "reason": "Selecting the pathway requires the item-specific functional or pathway annotation; the sequence alone does not meaningfully distinguish the choices."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "The supplied sequence does not resolve the pathway, but the reviewer-only evidence supports one option rather than establishing multiple defensible choices."
  },
  "important_caveats": [
    "The reviewer-only accession and pathway annotation were not supplied to the evaluated model.",
    "The actual source snapshot used by the author is unknown; a sequence-matched historical UniProt record also contains the pathway annotation."
  ]
}
```

</details>

## Before: Qwen3.8-Flash-Next-NVFP4

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The UniProt entry A0A0L1JEZ9 (RSTN6_ASPN3) explicitly annotates PATHWAY as 'Antifungal biosynthesis' with experimental evidence code ECO:0000269 from PubMed:33857369. The protein is a FAD-dependent monooxygenase rstn6, part of the restricticin biosynthetic gene cluster (a CYP51 inhibitor, i.e., an antifungal compound). The sequence matches exactly (575 AA, SHA256 confirmed). The pathway annotation is experimentally supported, not merely computational.

Citations as saved: [C1](#evidence-c1), [C4](#evidence-c4), [C5](#evidence-c5), [C6](#evidence-c6), [H1](#evidence-h1), [H2](#evidence-h2), [H3](#evidence-h3).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

> One could argue from sequence that a 575-residue FAD-dependent monooxygenase is unlikely to be a primary amino acid biosynthesis enzyme (eliminating B and D), as those pathways use distinct enzyme classes (e.g., threonine synthase, dihydroxy-acid dehydratase). However, distinguishing 'antifungal biosynthesis' (A) from 'alkaloid biosynthesis' (C) requires knowing that this protein belongs to the restricticin biosynthetic gene cluster and that restricticin is a CYP51 inhibitor with antifungal activity—information not derivable from the amino acid sequence alone.


**Missing item-specific fact**

> Knowledge that this specific FAD-dependent monooxygenase (rstn6) is a member of the restricticin biosynthetic gene cluster in Aspergillus nomiae, and that restricticin is a natural-product CYP51 inhibitor classified as an antifungal agent. The sequence provides no motif or domain architecture that uniquely distinguishes antifungal secondary metabolite biosynthesis from alkaloid biosynthesis.


**Reason**

> The sequence identifies a FAD-dependent monooxygenase, a general enzyme class present in many secondary metabolite pathways. Correctly choosing 'Antifungal biosynthesis' over 'Alkaloid biosynthesis' requires item-specific knowledge of the restricticin BGC and the biological activity of its product, which is a database/experimental annotation rather than a sequence-inferable property.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[]
```

> While A and C are both secondary metabolite biosynthesis pathways involving FAD-dependent monooxygenases, the UniProt annotation unambiguously assigns 'Antifungal biosynthesis' with experimental evidence. Options B and D are clearly inappropriate for a large FAD-dependent monooxygenase. The question has a single correct answer per the authoritative annotation.


### Important caveats

- The pathway annotation 'Antifungal biosynthesis' is based on experimental evidence (ECO:0000269) from a 2021 JACS paper demonstrating restricticin's CYP51 inhibitory activity, not merely computational prediction.
- The protein was integrated into Swiss-Prot on 2025-02-05; the author's source snapshot date is unknown, but the sequence has been stable since 2015.
- The term 'Antifungal biosynthesis' is a UniProt-specific pathway category for secondary metabolite gene clusters producing antifungal compounds; it is not a standard KEGG or MetaCyc pathway name.
- The evaluated model receives only the raw sequence and four options with no organism, gene name, or cluster context.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "One could argue from sequence that a 575-residue FAD-dependent monooxygenase is unlikely to be a primary amino acid biosynthesis enzyme (eliminating B and D), as those pathways use distinct enzyme classes (e.g., threonine synthase, dihydroxy-acid dehydratase). However, distinguishing 'antifungal biosynthesis' (A) from 'alkaloid biosynthesis' (C) requires knowing that this protein belongs to the restricticin biosynthetic gene cluster and that restricticin is a CYP51 inhibitor with antifungal activity—information not derivable from the amino acid sequence alone.",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "Knowledge that this specific FAD-dependent monooxygenase (rstn6) is a member of the restricticin biosynthetic gene cluster in Aspergillus nomiae, and that restricticin is a natural-product CYP51 inhibitor classified as an antifungal agent. The sequence provides no motif or domain architecture that uniquely distinguishes antifungal secondary metabolite biosynthesis from alkaloid biosynthesis.",
    "reason": "The sequence identifies a FAD-dependent monooxygenase, a general enzyme class present in many secondary metabolite pathways. Correctly choosing 'Antifungal biosynthesis' over 'Alkaloid biosynthesis' requires item-specific knowledge of the restricticin BGC and the biological activity of its product, which is a database/experimental annotation rather than a sequence-inferable property."
  },
  "case_id": "pathway_0132",
  "expected_answer_check": {
    "evidence_ids": [
      "C1",
      "C4",
      "C5",
      "C6",
      "H1",
      "H2",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The UniProt entry A0A0L1JEZ9 (RSTN6_ASPN3) explicitly annotates PATHWAY as 'Antifungal biosynthesis' with experimental evidence code ECO:0000269 from PubMed:33857369. The protein is a FAD-dependent monooxygenase rstn6, part of the restricticin biosynthetic gene cluster (a CYP51 inhibitor, i.e., an antifungal compound). The sequence matches exactly (575 AA, SHA256 confirmed). The pathway annotation is experimentally supported, not merely computational."
  },
  "important_caveats": [
    "The pathway annotation 'Antifungal biosynthesis' is based on experimental evidence (ECO:0000269) from a 2021 JACS paper demonstrating restricticin's CYP51 inhibitory activity, not merely computational prediction.",
    "The protein was integrated into Swiss-Prot on 2025-02-05; the author's source snapshot date is unknown, but the sequence has been stable since 2015.",
    "The term 'Antifungal biosynthesis' is a UniProt-specific pathway category for secondary metabolite gene clusters producing antifungal compounds; it is not a standard KEGG or MetaCyc pathway name.",
    "The evaluated model receives only the raw sequence and four options with no organism, gene name, or cluster context."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "While A and C are both secondary metabolite biosynthesis pathways involving FAD-dependent monooxygenases, the UniProt annotation unambiguously assigns 'Antifungal biosynthesis' with experimental evidence. Options B and D are clearly inappropriate for a large FAD-dependent monooxygenase. The question has a single correct answer per the authoritative annotation."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text


{
  "case_id": "pathway_0132",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The UniProt entry A0A0L1JEZ9 (RSTN6_ASPN3) explicitly annotates PATHWAY as 'Antifungal biosynthesis' with experimental evidence code ECO:0000269 from PubMed:33857369. The protein is a FAD-dependent monooxygenase rstn6, part of the restricticin biosynthetic gene cluster (a CYP51 inhibitor, i.e., an antifungal compound). The sequence matches exactly (575 AA, SHA256 confirmed). The pathway annotation is experimentally supported, not merely computational.",
    "evidence_ids": ["C1", "C4", "C5", "C6", "H1", "H2", "H3"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "One could argue from sequence that a 575-residue FAD-dependent monooxygenase is unlikely to be a primary amino acid biosynthesis enzyme (eliminating B and D), as those pathways use distinct enzyme classes (e.g., threonine synthase, dihydroxy-acid dehydratase). However, distinguishing 'antifungal biosynthesis' (A) from 'alkaloid biosynthesis' (C) requires knowing that this protein belongs to the restricticin biosynthetic gene cluster and that restricticin is a CYP51 inhibitor with antifungal activity—information not derivable from the amino acid sequence alone.",
    "missing_item_specific_fact": "Knowledge that this specific FAD-dependent monooxygenase (rstn6) is a member of the restricticin biosynthetic gene cluster in Aspergillus nomiae, and that restricticin is a natural-product CYP51 inhibitor classified as an antifungal agent. The sequence provides no motif or domain architecture that uniquely distinguishes antifungal secondary metabolite biosynthesis from alkaloid biosynthesis.",
    "reason": "The sequence identifies a FAD-dependent monooxygenase, a general enzyme class present in many secondary metabolite pathways. Correctly choosing 'Antifungal biosynthesis' over 'Alkaloid biosynthesis' requires item-specific knowledge of the restricticin BGC and the biological activity of its product, which is a database/experimental annotation rather than a sequence-inferable property."
  },
  "question_ambiguity": {
    "multiple_defensible_options": [],
    "reason": "While A and C are both secondary metabolite biosynthesis pathways involving FAD-dependent monooxygenases, the UniProt annotation unambiguously assigns 'Antifungal biosynthesis' with experimental evidence. Options B and D are clearly inappropriate for a large FAD-dependent monooxygenase. The question has a single correct answer per the authoritative annotation."
  },
  "important_caveats": [
    "The pathway annotation 'Antifungal biosynthesis' is based on experimental evidence (ECO:0000269) from a 2021 JACS paper demonstrating restricticin's CYP51 inhibitory activity, not merely computational prediction.",
    "The protein was integrated into Swiss-Prot on 2025-02-05; the author's source snapshot date is unknown, but the sequence has been stable since 2015.",
    "The term 'Antifungal biosynthesis' is a UniProt-specific pathway category for secondary metabolite gene clusters producing antifungal compounds; it is not a standard KEGG or MetaCyc pathway name.",
    "The evaluated model receives only the raw sequence and four options with no organism, gene name, or cluster context."
  ]
}
```

</details>

## After: GPT-6 Luna

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> A sequence-matched UniProt annotation assigns this protein to antifungal biosynthesis and cites a 2021 publication with experimental-evidence status. This supports the keyed pathway annotation, though the excerpts do not independently establish the experiment's details.

Citations as saved: [H3](#evidence-h3), [C5](#evidence-c5).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

Empty string, as saved.


**Missing item-specific fact**

> The protein's specific biosynthetic-cluster or product association, which identifies the pathway as antifungal rather than another specialized-metabolite pathway.


**Reason**

> The sequence has features consistent with a FAD-dependent monooxygenase, a broad enzyme class that can participate in specialized metabolism. That may make amino-acid-biosynthesis choices less plausible, but does not meaningfully distinguish antifungal biosynthesis from alkaloid biosynthesis without pathway-specific family or cluster evidence.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[
  "A",
  "C"
]
```

> From the sequence and general enzyme-class inference alone, a specialized-metabolism monooxygenase does not distinguish antifungal-product biosynthesis from alkaloid biosynthesis. The source annotation supports A, but that target-specific evidence was not in the original input.


### Important caveats

- The historical sequence-matched annotation supports the key, but the exact author source snapshot is unknown.
- The source evidence supports a database pathway annotation; it is not a comprehensive independent review of the cited study.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "The protein's specific biosynthetic-cluster or product association, which identifies the pathway as antifungal rather than another specialized-metabolite pathway.",
    "reason": "The sequence has features consistent with a FAD-dependent monooxygenase, a broad enzyme class that can participate in specialized metabolism. That may make amino-acid-biosynthesis choices less plausible, but does not meaningfully distinguish antifungal biosynthesis from alkaloid biosynthesis without pathway-specific family or cluster evidence."
  },
  "case_id": "pathway_0132",
  "expected_answer_check": {
    "evidence_ids": [
      "H3",
      "C5"
    ],
    "judgment": "supported",
    "reason": "A sequence-matched UniProt annotation assigns this protein to antifungal biosynthesis and cites a 2021 publication with experimental-evidence status. This supports the keyed pathway annotation, though the excerpts do not independently establish the experiment's details."
  },
  "important_caveats": [
    "The historical sequence-matched annotation supports the key, but the exact author source snapshot is unknown.",
    "The source evidence supports a database pathway annotation; it is not a comprehensive independent review of the cited study."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [
      "A",
      "C"
    ],
    "reason": "From the sequence and general enzyme-class inference alone, a specialized-metabolism monooxygenase does not distinguish antifungal-product biosynthesis from alkaloid biosynthesis. The source annotation supports A, but that target-specific evidence was not in the original input."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text
{
  "case_id": "pathway_0132",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "A sequence-matched UniProt annotation assigns this protein to antifungal biosynthesis and cites a 2021 publication with experimental-evidence status. This supports the keyed pathway annotation, though the excerpts do not independently establish the experiment's details.",
    "evidence_ids": ["H3", "C5"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "",
    "missing_item_specific_fact": "The protein's specific biosynthetic-cluster or product association, which identifies the pathway as antifungal rather than another specialized-metabolite pathway.",
    "reason": "The sequence has features consistent with a FAD-dependent monooxygenase, a broad enzyme class that can participate in specialized metabolism. That may make amino-acid-biosynthesis choices less plausible, but does not meaningfully distinguish antifungal biosynthesis from alkaloid biosynthesis without pathway-specific family or cluster evidence."
  },
  "question_ambiguity": {
    "multiple_defensible_options": ["A", "C"],
    "reason": "From the sequence and general enzyme-class inference alone, a specialized-metabolism monooxygenase does not distinguish antifungal-product biosynthesis from alkaloid biosynthesis. The source annotation supports A, but that target-specific evidence was not in the original input."
  },
  "important_caveats": [
    "The historical sequence-matched annotation supports the key, but the exact author source snapshot is unknown.",
    "The source evidence supports a database pathway annotation; it is not a comprehensive independent review of the cited study."
  ]
}
```

</details>

## After: Qwen3.8-Flash-Next-NVFP4

**Output usability:** usable output: format-valid review.
**Canonical saved status:** `valid_review`.

### Expected-answer support: supported

> The UniProt entry (A0A0L1JEZ9) annotates this protein as 'FAD-dependent monooxygenase rstn6' / 'Restricticin biosynthesis cluster protein 6' with the pathway 'Antifungal biosynthesis' supported by experimental evidence (ECO:0000269, PubMed:33857369). Restricticin is a natural product CYP51 inhibitor with antifungal activity, and this enzyme is part of its biosynthetic gene cluster. The sequence matches the benchmark sequence exactly.

Citations as saved: [C4](#evidence-c4), [C5](#evidence-c5), [C6](#evidence-c6), [H3](#evidence-h3).

### Reasoning versus lookup: lookup-dependent

**Discriminating biological argument**

> The sequence exhibits hallmarks of a FAD-dependent monooxygenase: N-terminal hydrophobic signal peptide, multiple glycine-rich motifs (GAG, GGR, GAGP), and a domain architecture consistent with FAD-binding oxidoreductases (~575 aa). This allows elimination of B (L-methionine biosynthesis; key enzymes are PLP-dependent or acetyltransferases) and D (L-valine biosynthesis; involves acetohydroxy acid synthase, dihydroxy-acid dehydratase, etc.). However, distinguishing A (Antifungal biosynthesis) from C (Alkaloid biosynthesis) is very difficult from sequence alone. FAD-dependent monooxygenases are common tailoring enzymes in BOTH fungal NRPS/PKS-derived secondary metabolite clusters (which produce many antifungals) AND alkaloid biosynthetic gene clusters (e.g., berberine bridge enzyme, flavin-dependent oxidases in ergot alkaloid pathways). The specific assignment to 'antifungal biosynthesis' requires knowing that this enzyme belongs to the restricticin BGC (a CYP51-inhibitor pathway) rather than an alkaloid BGC.


**Missing item-specific fact**

> The specific biosynthetic gene cluster context: that this FAD-dependent monooxygenase (rstn6) is a member of the restricticin biosynthetic gene cluster in Aspergillus nomiae, whose product is a CYP51-inhibiting antifungal compound, rather than being part of an alkaloid biosynthetic cluster.


**Reason**

> While B and D can be eliminated by recognizing the FAD-dependent monooxygenase architecture (incompatible with amino acid biosynthesis enzymes), the critical A-vs-C distinction cannot be made from sequence features or general fungal biochemistry knowledge. FAD-dependent monooxygenases are well-documented in both antifungal and alkaloid biosynthetic gene clusters. The correct answer depends on knowing the specific BGC membership (restricticin cluster) of this particular enzyme.


### Question ambiguity

**Multiple defensible options, exactly as saved:**

```json
[
  "A",
  "C"
]
```

> From sequence alone, a FAD-dependent monooxygenase in a fungal context could plausibly participate in either antifungal secondary metabolite biosynthesis (A) or alkaloid biosynthesis (C). Both pathways employ FAD-dependent monooxygenases as tailoring/oxidation enzymes. Without the specific BGC context, both A and C are defensible based on the enzyme's catalytic class.


### Important caveats

- The pathway annotation 'Antifungal biosynthesis' is a UniProt-specific label for the restricticin BGC; it is not a standard KEGG or MetaCyc pathway name, which may affect generalizability.
- The evidence code ECO:0000269 indicates experimental support (from the 2021 JACS paper), not merely computational inference.
- The question provides no organism, gene name, or BGC context in the model input, making the A-vs-C distinction reliant on memorizing this specific protein's annotation.
- A weak statistical argument exists that standalone FAD-dependent monooxygenases in fungal BGCs are more commonly NRPS/PKS tailoring enzymes (antifungal) than alkaloid pathway enzymes, but this is not strong enough to definitively exclude C.

<details>
<summary>Complete saved parsed visible review</summary>

```json
{
  "answerability_check": {
    "discriminating_biological_argument": "The sequence exhibits hallmarks of a FAD-dependent monooxygenase: N-terminal hydrophobic signal peptide, multiple glycine-rich motifs (GAG, GGR, GAGP), and a domain architecture consistent with FAD-binding oxidoreductases (~575 aa). This allows elimination of B (L-methionine biosynthesis; key enzymes are PLP-dependent or acetyltransferases) and D (L-valine biosynthesis; involves acetohydroxy acid synthase, dihydroxy-acid dehydratase, etc.). However, distinguishing A (Antifungal biosynthesis) from C (Alkaloid biosynthesis) is very difficult from sequence alone. FAD-dependent monooxygenases are common tailoring enzymes in BOTH fungal NRPS/PKS-derived secondary metabolite clusters (which produce many antifungals) AND alkaloid biosynthetic gene clusters (e.g., berberine bridge enzyme, flavin-dependent oxidases in ergot alkaloid pathways). The specific assignment to 'antifungal biosynthesis' requires knowing that this enzyme belongs to the restricticin BGC (a CYP51-inhibitor pathway) rather than an alkaloid BGC.",
    "judgment": "lookup_or_memorization_dependent",
    "missing_item_specific_fact": "The specific biosynthetic gene cluster context: that this FAD-dependent monooxygenase (rstn6) is a member of the restricticin biosynthetic gene cluster in Aspergillus nomiae, whose product is a CYP51-inhibiting antifungal compound, rather than being part of an alkaloid biosynthetic cluster.",
    "reason": "While B and D can be eliminated by recognizing the FAD-dependent monooxygenase architecture (incompatible with amino acid biosynthesis enzymes), the critical A-vs-C distinction cannot be made from sequence features or general fungal biochemistry knowledge. FAD-dependent monooxygenases are well-documented in both antifungal and alkaloid biosynthetic gene clusters. The correct answer depends on knowing the specific BGC membership (restricticin cluster) of this particular enzyme."
  },
  "case_id": "pathway_0132",
  "expected_answer_check": {
    "evidence_ids": [
      "C4",
      "C5",
      "C6",
      "H3"
    ],
    "judgment": "supported",
    "reason": "The UniProt entry (A0A0L1JEZ9) annotates this protein as 'FAD-dependent monooxygenase rstn6' / 'Restricticin biosynthesis cluster protein 6' with the pathway 'Antifungal biosynthesis' supported by experimental evidence (ECO:0000269, PubMed:33857369). Restricticin is a natural product CYP51 inhibitor with antifungal activity, and this enzyme is part of its biosynthetic gene cluster. The sequence matches the benchmark sequence exactly."
  },
  "important_caveats": [
    "The pathway annotation 'Antifungal biosynthesis' is a UniProt-specific label for the restricticin BGC; it is not a standard KEGG or MetaCyc pathway name, which may affect generalizability.",
    "The evidence code ECO:0000269 indicates experimental support (from the 2021 JACS paper), not merely computational inference.",
    "The question provides no organism, gene name, or BGC context in the model input, making the A-vs-C distinction reliant on memorizing this specific protein's annotation.",
    "A weak statistical argument exists that standalone FAD-dependent monooxygenases in fungal BGCs are more commonly NRPS/PKS tailoring enzymes (antifungal) than alkaloid pathway enzymes, but this is not strong enough to definitively exclude C."
  ],
  "question_ambiguity": {
    "multiple_defensible_options": [
      "A",
      "C"
    ],
    "reason": "From sequence alone, a FAD-dependent monooxygenase in a fungal context could plausibly participate in either antifungal secondary metabolite biosynthesis (A) or alkaloid biosynthesis (C). Both pathways employ FAD-dependent monooxygenases as tailoring/oxidation enzymes. Without the specific BGC context, both A and C are defensible based on the enzyme's catalytic class."
  }
}
```

</details>

<details>
<summary>Exact saved visible final text</summary>

```text


{
  "case_id": "pathway_0132",
  "expected_answer_check": {
    "judgment": "supported",
    "reason": "The UniProt entry (A0A0L1JEZ9) annotates this protein as 'FAD-dependent monooxygenase rstn6' / 'Restricticin biosynthesis cluster protein 6' with the pathway 'Antifungal biosynthesis' supported by experimental evidence (ECO:0000269, PubMed:33857369). Restricticin is a natural product CYP51 inhibitor with antifungal activity, and this enzyme is part of its biosynthetic gene cluster. The sequence matches the benchmark sequence exactly.",
    "evidence_ids": ["C4", "C5", "C6", "H3"]
  },
  "answerability_check": {
    "judgment": "lookup_or_memorization_dependent",
    "discriminating_biological_argument": "The sequence exhibits hallmarks of a FAD-dependent monooxygenase: N-terminal hydrophobic signal peptide, multiple glycine-rich motifs (GAG, GGR, GAGP), and a domain architecture consistent with FAD-binding oxidoreductases (~575 aa). This allows elimination of B (L-methionine biosynthesis; key enzymes are PLP-dependent or acetyltransferases) and D (L-valine biosynthesis; involves acetohydroxy acid synthase, dihydroxy-acid dehydratase, etc.). However, distinguishing A (Antifungal biosynthesis) from C (Alkaloid biosynthesis) is very difficult from sequence alone. FAD-dependent monooxygenases are common tailoring enzymes in BOTH fungal NRPS/PKS-derived secondary metabolite clusters (which produce many antifungals) AND alkaloid biosynthetic gene clusters (e.g., berberine bridge enzyme, flavin-dependent oxidases in ergot alkaloid pathways). The specific assignment to 'antifungal biosynthesis' requires knowing that this enzyme belongs to the restricticin BGC (a CYP51-inhibitor pathway) rather than an alkaloid BGC.",
    "missing_item_specific_fact": "The specific biosynthetic gene cluster context: that this FAD-dependent monooxygenase (rstn6) is a member of the restricticin biosynthetic gene cluster in Aspergillus nomiae, whose product is a CYP51-inhibiting antifungal compound, rather than being part of an alkaloid biosynthetic cluster.",
    "reason": "While B and D can be eliminated by recognizing the FAD-dependent monooxygenase architecture (incompatible with amino acid biosynthesis enzymes), the critical A-vs-C distinction cannot be made from sequence features or general fungal biochemistry knowledge. FAD-dependent monooxygenases are well-documented in both antifungal and alkaloid biosynthetic gene clusters. The correct answer depends on knowing the specific BGC membership (restricticin cluster) of this particular enzyme."
  },
  "question_ambiguity": {
    "multiple_defensible_options": ["A", "C"],
    "reason": "From sequence alone, a FAD-dependent monooxygenase in a fungal context could plausibly participate in either antifungal secondary metabolite biosynthesis (A) or alkaloid biosynthesis (C). Both pathways employ FAD-dependent monooxygenases as tailoring/oxidation enzymes. Without the specific BGC context, both A and C are defensible based on the enzyme's catalytic class."
  },
  "important_caveats": [
    "The pathway annotation 'Antifungal biosynthesis' is a UniProt-specific label for the restricticin BGC; it is not a standard KEGG or MetaCyc pathway name, which may affect generalizability.",
    "The evidence code ECO:0000269 indicates experimental support (from the 2021 JACS paper), not merely computational inference.",
    "The question provides no organism, gene name, or BGC context in the model input, making the A-vs-C distinction reliant on memorizing this specific protein's annotation.",
    "A weak statistical argument exists that standalone FAD-dependent monooxygenases in fungal BGCs are more commonly NRPS/PKS tailoring enzymes (antifungal) than alkaloid pathway enzymes, but this is not strong enough to definitively exclude C."
  ]
}
```

</details>

## Existing project source checks of the old Luna review only

These unchanged notes concern the earlier Luna claims. They do not validate either new review or the old Qwen review. No new scientific adjudication was performed.

## Project source-check notes

These project-authored, AI-assisted checks assess specific source claims. They are not expert adjudication and do not replace Luna’s saved review or the author key.

No additional case-specific project note was recorded. Citation membership checks do not establish that every scientific argument is correct.

## Complete reviewer-only evidence and qualifications

All excerpts supplied in the original and revised reviewer user message follow. This material was not available to the original evaluated model. Accession identity came from dataset image-path metadata. Source support and transferable discrimination are separate judgments.

**Applicability metadata, unchanged:**

```json
{
  "requested_accession": "A0A0L1JEZ9",
  "identity_origin": "reviewer-only accession inferred mechanically from original dataset image-path metadata; this accession/metadata was absent from evaluated model input",
  "benchmark_sequence_sha256": "72d989da09092e85859ae61883a12245775ecdadf4d6629bb5bc6ae1571ed767",
  "benchmark_sequence_length": 575,
  "current_status": "retrieved",
  "current_sequence_comparison": "matched",
  "current_entry_audit": {
    "entryVersion": 30,
    "firstPublicDate": "2025-02-05",
    "lastAnnotationUpdateDate": "2026-09-02",
    "lastSequenceUpdateDate": "2015-11-11",
    "sequenceVersion": 1
  },
  "current_uniprot_release": "2026_03",
  "current_record_sha256": "4d01240ed409683b6301eb09ae4241d48ebba4a1ee93a1a1f52670b1170dd1f9",
  "current_source_sequence_sha256": "72d989da09092e85859ae61883a12245775ecdadf4d6629bb5bc6ae1571ed767",
  "current_source_sequence_length": 575,
  "historical_status": "retrieved",
  "historical_cutoff_date": "2026-05-07",
  "historical_sequence_comparison": "matched",
  "selected_historical_entry_version": 28,
  "selected_historical_version": {
    "accession": "A0A0L1JEZ9",
    "database": "Swiss-Prot",
    "entryVersion": 28,
    "firstRelease": "2026_01/2026_01",
    "firstReleaseDate": "28-Jan-2026",
    "lastRelease": "2026_01/2026_01",
    "lastReleaseDate": "28-Jan-2026",
    "name": "RSTN6_ASPN3",
    "sequenceVersion": 1
  },
  "selected_historical_record_sha256": "2c7b4bf2d2ac6a871c693107d6eec756dfa45dd401fe7ff200f0a7d14748ef8a",
  "selected_historical_source_sequence_sha256": "72d989da09092e85859ae61883a12245775ecdadf4d6629bb5bc6ae1571ed767",
  "selected_historical_source_sequence_length": 575,
  "latest_at_cutoff_sequence_comparison": "matched",
  "historical_sequence_versions_checked": [
    {
      "entry_version": 28,
      "exact_sequence_comparison": "matched",
      "sequence_version": 1
    }
  ],
  "actual_author_source_snapshot": "unknown",
  "numbering": "Canonical entry coordinates; construct or isoform numbering is not assumed."
}
```

**Qualifications, unchanged:**

- All evidence and source identity in this section are reviewer-only and were absent from the evaluated model input.
- UniProt annotations may be experimental, computational, or transferred by similarity; evidence codes and qualifiers are retained.
- The 2026-05-07 cutoff approximates the pinned repository date; the author data-construction date and exact source snapshot remain unknown.
- Selected source fields are excerpts; missing annotation is not evidence of falsehood. Primary papers were not comprehensively retrieved or independently validated.

### Evidence C1

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEZ9.json)

```json
{
  "evidence_id": "C1",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0L1JEZ9.json",
  "source_sha256": "4d01240ed409683b6301eb09ae4241d48ebba4a1ee93a1a1f52670b1170dd1f9",
  "retrieved_utc": "2026-11-02T04:24:14.766738+00:00",
  "json_pointer": "/primaryAccession",
  "excerpt": "\"A0A0L1JEZ9\"",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C2

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEZ9.json)

```json
{
  "evidence_id": "C2",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0L1JEZ9.json",
  "source_sha256": "4d01240ed409683b6301eb09ae4241d48ebba4a1ee93a1a1f52670b1170dd1f9",
  "retrieved_utc": "2026-11-02T04:24:14.766738+00:00",
  "json_pointer": "/entryAudit",
  "excerpt": "{\"entryVersion\":30,\"firstPublicDate\":\"2025-02-05\",\"lastAnnotationUpdateDate\":\"2026-09-02\",\"lastSequenceUpdateDate\":\"2015-11-11\",\"sequenceVersion\":1}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C3

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEZ9.json)

```json
{
  "evidence_id": "C3",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0L1JEZ9.json",
  "source_sha256": "4d01240ed409683b6301eb09ae4241d48ebba4a1ee93a1a1f52670b1170dd1f9",
  "retrieved_utc": "2026-11-02T04:24:14.766738+00:00",
  "json_pointer": "/organism",
  "excerpt": "{\"lineage\":[\"Eukaryota\",\"Fungi\",\"Dikarya\",\"Ascomycota\",\"Pezizomycotina\",\"Eurotiomycetes\",\"Eurotiomycetidae\",\"Eurotiales\",\"Aspergillaceae\",\"Aspergillus\",\"Circumdati\"],\"scientificName\":\"Aspergillus nomiae NRRL (strain ATCC 15546 / NRRL 13137 / CBS 260.88 / M93)\",\"taxonId\":1509407}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C4

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEZ9.json)

```json
{
  "evidence_id": "C4",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0L1JEZ9.json",
  "source_sha256": "4d01240ed409683b6301eb09ae4241d48ebba4a1ee93a1a1f52670b1170dd1f9",
  "retrieved_utc": "2026-11-02T04:24:14.766738+00:00",
  "json_pointer": "/proteinDescription",
  "excerpt": "{\"alternativeNames\":[{\"fullName\":{\"evidences\":[{\"evidenceCode\":\"ECO:0000303\",\"id\":\"33857369\",\"source\":\"PubMed\"}],\"value\":\"Restricticin biosynthesis cluster protein 6\"}}],\"flag\":\"Precursor\",\"recommendedName\":{\"ecNumbers\":[{\"evidences\":[{\"evidenceCode\":\"ECO:0000305\",\"id\":\"33857369\",\"source\":\"PubMed\"}],\"value\":\"1.-.-.-\"}],\"fullName\":{\"evidences\":[{\"evidenceCode\":\"ECO:0000303\",\"id\":\"33857369\",\"source\":\"PubMed\"}],\"value\":\"FAD-dependent monooxygenase rstn6\"}}}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C5

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEZ9.json)

```json
{
  "evidence_id": "C5",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0L1JEZ9.json",
  "source_sha256": "4d01240ed409683b6301eb09ae4241d48ebba4a1ee93a1a1f52670b1170dd1f9",
  "retrieved_utc": "2026-11-02T04:24:14.766738+00:00",
  "json_pointer": "/comments/2",
  "excerpt": "{\"commentType\":\"PATHWAY\",\"texts\":[{\"evidences\":[{\"evidenceCode\":\"ECO:0000269\",\"id\":\"33857369\",\"source\":\"PubMed\"}],\"value\":\"Antifungal biosynthesis\"}]}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence C6

[UniProtKB current entry](https://rest.uniprot.org/uniprotkb/A0A0L1JEZ9.json)

```json
{
  "evidence_id": "C6",
  "source": "UniProtKB current entry",
  "url": "https://rest.uniprot.org/uniprotkb/A0A0L1JEZ9.json",
  "source_sha256": "4d01240ed409683b6301eb09ae4241d48ebba4a1ee93a1a1f52670b1170dd1f9",
  "retrieved_utc": "2026-11-02T04:24:14.766738+00:00",
  "json_pointer": "/references/1",
  "excerpt": "{\"citation\":{\"authors\":[\"Liu N.\",\"Abramyan E.D.\",\"Cheng W.\",\"Perlatti B.\",\"Harvey C.J.B.\",\"Bills G.F.\",\"Tang Y.\"],\"citationCrossReferences\":[{\"database\":\"PubMed\",\"id\":\"33857369\"},{\"database\":\"DOI\",\"id\":\"10.1021/jacs.1c01516\"}],\"citationType\":\"journal article\",\"firstPage\":\"6043\",\"id\":\"33857369\",\"journal\":\"J. Am. Chem. Soc.\",\"lastPage\":\"6047\",\"publicationDate\":\"2021\",\"title\":\"Targeted genome mining reveals the biosynthetic gene clusters of natural product CYP51 inhibitors.\",\"volume\":\"143\"},\"referenceNumber\":2,\"referencePositions\":[\"FUNCTION\",\"PATHWAY\"]}",
  "excerpt_format": "canonical JSON value at JSON pointer",
  "source_scope": "current snapshot; actual author source snapshot unknown",
  "sequence_comparison": "matched"
}
```

### Evidence H1

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A0L1JEZ9?format=txt&versions=28)

```json
{
  "evidence_id": "H1",
  "source": "UniSave archived UniProt entry",
  "url": "https://rest.uniprot.org/unisave/A0A0L1JEZ9?format=txt&versions=28",
  "source_sha256": "2c7b4bf2d2ac6a871c693107d6eec756dfa45dd401fe7ff200f0a7d14748ef8a",
  "retrieved_utc": "2026-11-02T04:24:16.831471+00:00",
  "source_locator": "lines 1-16",
  "excerpt": "ID   RSTN6_ASPN3             Reviewed;         575 AA.\nAC   A0A0L1JEZ9;\nDT   05-FEB-2025, integrated into UniProtKB/Swiss-Prot.\nDT   11-NOV-2015, sequence version 1.\nDT   28-JAN-2026, entry version 28.\nDE   RecName: Full=FAD-dependent monooxygenase rstn6 {ECO:0000303|PubMed:33857369};\nDE            EC=1.-.-.- {ECO:0000305|PubMed:33857369};\nDE   AltName: Full=Restricticin biosynthesis cluster protein 6 {ECO:0000303|PubMed:33857369};\nDE   Flags: Precursor;\nGN   Name=rstn6 {ECO:0000303|PubMed:33857369}; ORFNames=ANOM_001445;\nOS   Aspergillus nomiae NRRL (strain ATCC 15546 / NRRL 13137 / CBS 260.88 /\nOS   M93).\nOC   Eukaryota; Fungi; Dikarya; Ascomycota; Pezizomycotina; Eurotiomycetes;\nOC   Eurotiomycetidae; Eurotiales; Aspergillaceae; Aspergillus;\nOC   Aspergillus subgen. Circumdati.\nOX   NCBI_TaxID=1509407;\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "entry_version": 28,
  "sequence_version": 1,
  "sequence_comparison": "matched"
}
```

### Evidence H2

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A0L1JEZ9?format=txt&versions=28)

```json
{
  "evidence_id": "H2",
  "source": "UniSave archived UniProt entry",
  "url": "https://rest.uniprot.org/unisave/A0A0L1JEZ9?format=txt&versions=28",
  "source_sha256": "2c7b4bf2d2ac6a871c693107d6eec756dfa45dd401fe7ff200f0a7d14748ef8a",
  "retrieved_utc": "2026-11-02T04:24:16.831471+00:00",
  "source_locator": "lines 25-32",
  "excerpt": "RN   [2]\nRP   FUNCTION, AND PATHWAY.\nRX   PubMed=33857369; DOI=10.1021/jacs.1c01516;\nRA   Liu N., Abramyan E.D., Cheng W., Perlatti B., Harvey C.J.B., Bills G.F.,\nRA   Tang Y.;\nRT   \"Targeted genome mining reveals the biosynthetic gene clusters of natural\nRT   product CYP51 inhibitors.\";\nRL   J. Am. Chem. Soc. 143:6043-6047(2021).\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "entry_version": 28,
  "sequence_version": 1,
  "sequence_comparison": "matched"
}
```

### Evidence H3

[UniSave archived UniProt entry](https://rest.uniprot.org/unisave/A0A0L1JEZ9?format=txt&versions=28)

```json
{
  "evidence_id": "H3",
  "source": "UniSave archived UniProt entry",
  "url": "https://rest.uniprot.org/unisave/A0A0L1JEZ9?format=txt&versions=28",
  "source_sha256": "2c7b4bf2d2ac6a871c693107d6eec756dfa45dd401fe7ff200f0a7d14748ef8a",
  "retrieved_utc": "2026-11-02T04:24:16.831471+00:00",
  "source_locator": "lines 50-50",
  "excerpt": "CC   -!- PATHWAY: Antifungal biosynthesis. {ECO:0000269|PubMed:33857369}.\n",
  "excerpt_format": "literal contiguous UniProt flat-file lines",
  "source_scope": "record released no later than 2026-05-07; actual author source snapshot unknown",
  "entry_version": 28,
  "sequence_version": 1,
  "sequence_comparison": "matched"
}
```

---

Original question/key: [pinned source](https://github.com/Rongdingyi/LiveProteinBench/blob/8b9710932511f816651fc1a7e8a1bc85c3c77767/dataset/QA/pathway.json), zero-based source row 132. © 2026 LiveProteinBench contributors; [CC BY 4.0](https://huggingface.co/datasets/LiveProteinBench/LiveProteinBench/blob/8428f64e33d53330f7745376d9c45de2d2c37eaf/LICENSE). [Source credits](../THIRD_PARTY_NOTICES.md).
